Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma

Fig. 2

Kaplan–Meier analysis of survival. The median survival after sorafenib treatment of patients in group A (patients receiving therapies targeting intrahepatic lesions; black line), group B (patients receiving systemic therapy alone, gray line), and group C (no subsequent therapy, dashedline) were 11.9, 5.8 and 3.6 months, respectively. Survival after sorafenib treatment of group A was significantly longer compared with that of group C (p < 0.001)

Back to article page